White Papers

Use this library as a technical resource.
All papers are downloadable in PDF format.

Key Challenges and Applied Approaches in Immuno-Oncology Trials

Key Challenges and Applied Approaches in Immuno-Oncology Trials

Immuno-oncology (I-0) has emerged as a promising area of research in oncology. The diverse investigational products that are currently under development in both the United States and the European Union target a plethora of biological mechanisms and pose unique challenges for clinical researchers. Innovative trial designs that take into account ethical considerations, adequate data collection and measurements, and the use of biomarkers as predictive or prognostic markers have helped researchers in designing and executing clinical trials that can provide valuable effiacy information. Furthermore, comprehensive planning and risk management in these high risk trials, which can have enhanced and unexpected toxicities, are imperative for the trial’s success and an adequate safety data collection. In this white paper we present in a clear and concise manner study design and execution strategies as well as data collection points and measurements necessary to undergo a successful I-O clinical trial.

RWE Study Design

RWE Study Design

Real-world evidence (RWE) derives from data collected outside of highly-controlled randomized clinical trials (patient reported outcomes, registries, databases, surveys, etc). RWE is rapidly gaining importance in healthcare decision making, as reflected in the various guidances that have already been issued or are planned by the EMA and FDA. In this review, we introduce the concept of RWE, describe the main RWE study designs, comment on the most relevant criteria that have to be taken into account, and include the TFS-RWE algorithm to find the most suitable design for you. Finally, we provide an overview of the European Union and United States regulations on RWE.

Epidermolysis Bullosa - Future perspectives in drug development

Epidermolysis Bullosa - Future perspectives in drug development

Epidermolysis bullosa is a heterogeneous group of rare disorders characterized by mechanical fragility of epithelial tissues. Researchers around the globe are investigating new therapies to improve the quality of life of patients with little or even non-available therapeutic options so far, particularly for the more severe variants. New horizons seems could be opened in the coming years in one of the ”Worst Disease You’ve Never Heard Of ”according to DEBRA (Dystrophic Epidermolysis Bullosa Research Association of America).

Register to unlock downloads

* indicates required

OPT-IN* – I accept the below conditions and give my consent to TRIAL FORM SUPPORT INTERNATIONAL AB and its affiliates for sending newsletters, scientific and company related information about TFS’ services, and to maintain and develop a business relationship with me. *

CONSENT FOR THE PROCESSING OF PERSONAL DATA
TFS TRIAL FORM SUPPORT INTERNATIONAL AB and its affiliates are responsible for the processing of the personal data you provide, and inform you that it will be processed in accordance with the provisions of the laws in force related to data protection and notably the Regulation (EU) 2016/679 of April 27th, 2016 with regard to the processing of personal data (GDPR).
How the data will be used: your data will be used in order to establish or maintain a business relationship and sending you communications about our services.
Data management rules: the data will be kept as long as there is a legitimate interest. When it is no longer necessary for this purpose, the data shall be eliminated with adequate security measures in order to guarantee the pseudonymization of the data or its total destruction.
Communication of the data: The data will not be communicated to third parties except if explicitly required by the law.
Rights of the data subject: as data subject, you will have the right to withdraw your consent at any time. You will also have the rights to access, to rectify, to erase your personal data as well as the right to ask for its portability or the limitation of its processing.
If you are not allowed to exercise these rights, a claim can be submitted before the Supervisory Authority.
Contact information to exercise your rights: Data protection rights, TFS International AB, Box 165, SE-221 00 Lund, Sweden. Email: data.protection@tfscro.com